A study of multinucleated giant cells in esophageal cancer
Hui Wang,Junjie Zhou,Jun Li,Yiqun Geng,Pei Meng,Changchun Ma,Ziqi Zhu,Weifeng Zhang,Liangli Hong,Yan Quan,Jiacong Wei,Qiongyi Huang,You Zhou,Zuoqing Su,Xiaoqing Zhu,Chuangzhen Chen,Shaobin Chen,Jiang Gu
DOI: https://doi.org/10.1016/j.clim.2020.108600
IF: 10.19
2021-01-01
Clinical Immunology
Abstract:OBJECTIVES: To evaluate the occurrence, abundance, distribution, nature and clinical significance of multinucleated giant cell (MGC) in esophageal cancer.MATERIALS AND METHODS: MGCs were examined with conventional pathology, immunohistochemistry and immunofluorescence in 107 esophageal cancer tissues. The findings were correlated to pathological diagnosis and clinical behavior of the cancers.RESULTS: MGCs were identified in 31.7% (34/107) of the cases. MGCs were positive for CD11c, CD11b, CD32, CD16, HLA-DR and MMP9, and negative for CD163, CD206 and CD64 giving a molecular profile of proinflammatory M1 but not immunosuppressive M2. MGCs were significantly related to decreased lymph node metastasis (p = 0.011), low pTNM stage (p = 0.044), favorable survival (p = 0.04), squamous cell cancer type rather than other histopathological subtypes (p = 0.020) and associated to better differentiation (p = 0.063).CONCLUSIONS: MGCs belong to M1 macrophage and perform phagocytosis and scavenging of cancer cells that would benefit patients' survival and could serve as a prognostic marker.
immunology